NYMOX

Serial Number 98369302
Registration 7578462
700

Registration Progress

Application Filed
Jan 22, 2024
Under Examination
Approved for Publication
Jul 9, 2024
Published for Opposition
Jul 9, 2024
Registered
Nov 26, 2024

Trademark Image

NYMOX

Basic Information

Serial Number
98369302
Registration Number
7578462
Filing Date
January 22, 2024
Registration Date
November 26, 2024
Published for Opposition
July 9, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 26, 2024
Registration
Registered
Classes
042

Rights Holder

Nymox Pharmaceutical Corporation

03
Address
Bay & Deveaux Streets
Nassau 0
BS

Ownership History

Nymox Pharmaceutical Corporation

Original Applicant
03
Nassau BS

Nymox Pharmaceutical Corporation

Owner at Publication
03
Nassau BS

Nymox Pharmaceutical Corporation

Original Registrant
03
Nassau BS

Legal Representation

Attorney
Patrick J. Jennings

USPTO Deadlines

Next Deadline
1962 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-26)
Due Date
November 26, 2030
Grace Period Ends
May 26, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

10 events
Date Code Type Description
Nov 26, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 26, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Sep 18, 2024 ISCR Z WITHDRAWN FROM ISSUE - OG REVIEW QUERY
Jul 9, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 9, 2024 PUBO A PUBLISHED FOR OPPOSITION
Jun 19, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 30, 2024 DOCK D ASSIGNED TO EXAMINER
May 30, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
May 22, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 22, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 042
Development of pharmaceutical preparations and medicines; Pharmaceutical product evaluation; Pharmaceutical research and development; Testing of pharmaceuticals; Medical and scientific research in the field of protein markers, subcellular pathology, cell death, cell proliferation, clinical models, genetic expression, assays, benign prostatic hyperplasia, and prostate cancer
First Use Anywhere: 20070500
First Use in Commerce: 20070500

Classification

International Classes
042

USPTO Documents

Click to view cached USPTO documents for this trademark

Only administrators can request new documents from USPTO